<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871428</url>
  </required_header>
  <id_info>
    <org_study_id>YC28037</org_study_id>
    <nct_id>NCT01871428</nct_id>
  </id_info>
  <brief_title>A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Na誰ve to Anti-Hyperglycemic Therapy</brief_title>
  <official_title>A Multicenter, Randomized, Doubleblind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared With Placebo in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Drug-Na誰ve to Antihyperglycemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled study will evaluate the&#xD;
      efficacy, safety and tolerability of aleglitazar monotherapy in patients with Type 2 diabetes&#xD;
      mellitus who are drug-na誰ve to anti-hyperglycemic therapy. Patients will be randomized to&#xD;
      receive either aleglitazar 150 mcg orally daily or placebo for 26 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lipids</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rates, defined as target HbA1c: &lt; 7.0%, &lt; 6.5% at Week 26</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostatic index of insulin sensitivity (by Homeostasis Model Assessment for Insulin Sensitivity [HOMA-IS])</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostatic index of beta cell function (by HOMA-BFC)</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of insulin sensitivity/cardiovascular risk</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Aleglitazar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aleglitazar</intervention_name>
    <description>150 mcg orally daily</description>
    <arm_group_label>Aleglitazar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching aleglitazar placebo orally daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient, &gt;/= 18 years of age&#xD;
&#xD;
          -  Diagnosis of Type 2 diabetes mellitus within 12 months prior to screening&#xD;
&#xD;
          -  Drug-na誰ve (defined as no anti-hyperglycemic medication for at least 12 weeks prior to&#xD;
             screening and for not longer than 3 consecutive months at any time in the past)&#xD;
&#xD;
          -  HbA1c &gt;/= 7% and &lt;/= 9.5% at screening or within 4 weeks prior to screening and at&#xD;
             pre-randomization visit&#xD;
&#xD;
          -  Fasting plasma glucose &lt;/= 13.3 mmol/L (&lt;/= 240 mg/dL) at pre-randomization visit&#xD;
&#xD;
          -  Agreement to maintain diet and exercise habits implemented during the run-in phase&#xD;
             during the full course of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, women intending to become pregnant during the study period, currently&#xD;
             lactating women, or women of child-bearing potential not using highly effective,&#xD;
             medically approved birth control methods&#xD;
&#xD;
          -  Diagnosis or history of:&#xD;
&#xD;
               1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary&#xD;
                  forms of diabetes&#xD;
&#xD;
               2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma&#xD;
                  within the past 6 months&#xD;
&#xD;
          -  Any previous treatment with thiazolidinedione or with a dual peroxisome proliferator&#xD;
             activated receptor (PPAR) agonist&#xD;
&#xD;
          -  Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12&#xD;
             weeks prior to screening with the exception of stable (&gt;= 1 month) statin therapy&#xD;
&#xD;
          -  Prior intolerance to fibrate&#xD;
&#xD;
          -  Triglycerides (fasting) &gt; 4.5 mmol/L (&gt; 400 mg/dL) at screening or within 4 weeks&#xD;
             prior to screening&#xD;
&#xD;
          -  Clinically apparent liver disease&#xD;
&#xD;
          -  Anemia at or within 4 weeks prior to screening&#xD;
&#xD;
          -  Inadequate renal function&#xD;
&#xD;
          -  Symptomatic congestive heart failure New York Heart Association (NYHA) Class II-IV at&#xD;
             screening&#xD;
&#xD;
          -  Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke&#xD;
             within 6 months prior to screening visit&#xD;
&#xD;
          -  Known macular edema at screening or prior to screening visit&#xD;
&#xD;
          -  Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ&#xD;
             carcinoma of the cervix, or in situ prostate cancer) within the past 5 years&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  History of active substance abuse (including alcohol) within the past 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shiyan</city>
        <zip>442000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alor Setar</city>
        <zip>05400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perak</city>
        <zip>33400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Malaysia</country>
  </location_countries>
  <removed_countries>
    <country>Philippines</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <disposition_first_submitted>August 9, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 9, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 11, 2016</disposition_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

